12 June 2017 - PHARMAC is pleased to announce the approval of a proposal relating to certain medicines in the neurology, immunology and nephrology therapeutic areas to take effect from 1 July 2017.

This was the subject of a consultation letter dated 21 April 2017.

In summary, the effect of the decision is that:

• Midazolam injection (Pfizer) will be available on a Practitioners Supply Order for use in status epilepticus
  
• Infliximab (Remicade) hospital restrictions will be widened to include treatment of neurosarcoidosis and Behçet’s disease, and the ocular inflammation criteria will be amended.
  
• Enoxaparin (Clexane) access will be widened to include use during home haemodialysis
  

Read PHARMAC press release